Company Overview
BRIDGEBIO PHARMA, INC.
BBIORevenue vs. Cost of Revenue
Revenue
Cost of Revenue
Total Operating Expenses vs. Operating Income
Total Operating Expenses
Operating Income
Net Income
Net Income
Revenue
502M
2025 FY
Net Income
-733M
2025 FY
Shares Outstanding
192M
2025 FY
EPS
-3.78USD
2025 FY
Company Information
SIC Code
2834
CIK Code
1743881
Exchange
Nasdaq
Location
US